Cancer name Colon Cancer
Cancer Type COCA
Immunotherapy type Immune Checkpoint Therapy
Treatment SP142
Drugstatus NA
Drugbank ID NA
Checkpoints PD-L1
Signature Type Cell
Signature CD45+ T cells
Official Symbol Mast cell
Mode of action CE_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description In the RFA plus a-PD-1 mAbs group, the infiltrating CD45+and CD8+ cells were increased as compared with the RFA or a-PD-1 alone. Importantly, the percentage of IFNg+ and TNFa+ CD8+ TIL in the RFA plus a-PD-1 mAbs-treated mice increased 3-fold more than the RFA-treated mice and 2-fold more thana-PD-1 mAbs-treatedmice. Meanwhile, the number of CD4+ TIL and the percentage of IFNg+ and TNFa+ CD4+ TIL were increased in mice receiving combined therapy.Quantitativereal-time PCR analysis showed that mRNA levels of IFNg and TNFa in contralateral tumor were significantlyelevated in the RFA plusa-PD-1–treated mice when comparedwiththe RFA or the a-PD-1 treatment alone groups.
PMID 26933175
Title PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.